KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $9.2 million.

  • Arbutus Biopharma's Operating Expenses fell 5966.46% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year decrease of 3167.29%. This contributed to the annual value of $82.5 million for FY2024, which is 1429.08% down from last year.
  • Arbutus Biopharma's Operating Expenses amounted to $9.2 million in Q3 2025, which was down 5966.46% from $9.3 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Operating Expenses registered a high of $28.8 million during Q4 2022, and its lowest value of $9.2 million during Q3 2025.
  • Its 5-year average for Operating Expenses is $21.8 million, with a median of $23.0 million in 2023.
  • Per our database at Business Quant, Arbutus Biopharma's Operating Expenses surged by 4309.79% in 2021 and then tumbled by 6031.15% in 2025.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Operating Expenses stood at $24.0 million in 2021, then rose by 20.02% to $28.8 million in 2022, then dropped by 20.53% to $22.9 million in 2023, then tumbled by 32.26% to $15.5 million in 2024, then plummeted by 40.75% to $9.2 million in 2025.
  • Its Operating Expenses stands at $9.2 million for Q3 2025, versus $9.3 million for Q2 2025 and $27.5 million for Q1 2025.